Viking Therapeutics Inc VKTX shares are trading higher on Friday.
BMO Capital initiated coverage on the stock with an Outperform rating and a price target of $14 per share.
Viking Therapeutics is a health care service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta.
Viking Therapeutics shares are trading up 3.23% at $7.36 on Friday. The stock has a 52-week range between $8.87 and $3.26.
Related Links:
Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
